JP2020530470A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530470A5 JP2020530470A5 JP2020507573A JP2020507573A JP2020530470A5 JP 2020530470 A5 JP2020530470 A5 JP 2020530470A5 JP 2020507573 A JP2020507573 A JP 2020507573A JP 2020507573 A JP2020507573 A JP 2020507573A JP 2020530470 A5 JP2020530470 A5 JP 2020530470A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- eye
- compound
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 20
- 210000001525 retina Anatomy 0.000 claims description 6
- 230000002792 vascular Effects 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
- 206010029113 Neovascularisation Diseases 0.000 claims description 4
- 206010053648 Vascular occlusion Diseases 0.000 claims description 4
- 208000021331 vascular occlusion disease Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims 8
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 238000002399 angioplasty Methods 0.000 claims 2
- 210000003161 choroid Anatomy 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 46
- 229940124130 Bcl inhibitor Drugs 0.000 description 12
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000003412 degenerative effect Effects 0.000 description 7
- 230000000302 ischemic effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 5
- 208000011325 dry age related macular degeneration Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 208000002177 Cataract Diseases 0.000 description 4
- 208000002691 Choroiditis Diseases 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 208000001351 Epiretinal Membrane Diseases 0.000 description 4
- 208000010412 Glaucoma Diseases 0.000 description 4
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 4
- 208000031471 Macular fibrosis Diseases 0.000 description 4
- 208000003971 Posterior uveitis Diseases 0.000 description 4
- 206010038848 Retinal detachment Diseases 0.000 description 4
- 208000017442 Retinal disease Diseases 0.000 description 4
- 206010038923 Retinopathy Diseases 0.000 description 4
- 206010064930 age-related macular degeneration Diseases 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000000642 iatrogenic effect Effects 0.000 description 4
- 230000004968 inflammatory condition Effects 0.000 description 4
- 230000004410 intraocular pressure Effects 0.000 description 4
- 208000002780 macular degeneration Diseases 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000004264 retinal detachment Effects 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 230000009327 senolytic effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- 206010015995 Eyelid ptosis Diseases 0.000 description 2
- 201000001925 Fuchs' endothelial dystrophy Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 206010025412 Macular dystrophy congenital Diseases 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 206010061323 Optic neuropathy Diseases 0.000 description 2
- 206010038910 Retinitis Diseases 0.000 description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 206010058990 Venous occlusion Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000021328 arterial occlusion Diseases 0.000 description 2
- 206010003230 arteritis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 208000020911 optic nerve disease Diseases 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 201000003004 ptosis Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001585 trabecular meshwork Anatomy 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000006439 vascular pathology Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 2
- 208000026726 vitreous disease Diseases 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 206010064714 Radiation retinopathy Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940125381 senolytic agent Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023076763A JP2023100864A (ja) | 2017-08-11 | 2023-05-08 | 老化細胞を排除する薬学的作用物質を用いる、黄斑変性症、緑内障、および糖尿病性網膜症などの眼病態の治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/675,171 | 2017-08-11 | ||
| US15/675,171 US20180000816A1 (en) | 2015-02-06 | 2017-08-11 | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| US201762579793P | 2017-10-31 | 2017-10-31 | |
| US62/579,793 | 2017-10-31 | ||
| PCT/US2018/046553 WO2019033119A1 (en) | 2017-08-11 | 2018-08-13 | TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076763A Division JP2023100864A (ja) | 2017-08-11 | 2023-05-08 | 老化細胞を排除する薬学的作用物質を用いる、黄斑変性症、緑内障、および糖尿病性網膜症などの眼病態の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530470A JP2020530470A (ja) | 2020-10-22 |
| JP2020530470A5 true JP2020530470A5 (enExample) | 2021-09-30 |
| JP7278257B2 JP7278257B2 (ja) | 2023-05-19 |
Family
ID=63254539
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507573A Active JP7278257B2 (ja) | 2017-08-11 | 2018-08-13 | 老化細胞を排除する薬学的作用物質を用いる、黄斑変性症、緑内障、および糖尿病性網膜症などの眼病態の治療 |
| JP2023076763A Pending JP2023100864A (ja) | 2017-08-11 | 2023-05-08 | 老化細胞を排除する薬学的作用物質を用いる、黄斑変性症、緑内障、および糖尿病性網膜症などの眼病態の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076763A Pending JP2023100864A (ja) | 2017-08-11 | 2023-05-08 | 老化細胞を排除する薬学的作用物質を用いる、黄斑変性症、緑内障、および糖尿病性網膜症などの眼病態の治療 |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP3441069B1 (enExample) |
| JP (2) | JP7278257B2 (enExample) |
| CN (1) | CN111372598A (enExample) |
| AU (2) | AU2018314280B2 (enExample) |
| CA (1) | CA3072673A1 (enExample) |
| MX (2) | MX2020001644A (enExample) |
| WO (1) | WO2019033119A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200354336A9 (en) | 2017-08-11 | 2020-11-12 | Unity Biotechnology, Inc. | Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells |
| US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
| CN117866015A (zh) | 2018-04-30 | 2024-04-12 | 联合生物科技公司 | 一种临床管理中使用的化合物及其用途 |
| US10717722B2 (en) | 2018-06-13 | 2020-07-21 | Unity Biotechnology, Inc. | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| AU2019296451B2 (en) | 2018-06-29 | 2021-04-29 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
| SG11202101032VA (en) * | 2018-08-20 | 2021-02-25 | Wuhan Neurophth Biotechnology Ltd Company | Compositions and methods for treating leber's hereditary optic neuropathy |
| JP2022548071A (ja) * | 2019-09-13 | 2022-11-16 | アメリカ合衆国 | 網膜変性を治療するための新薬の開発につながる標的 |
| CN113025633B (zh) | 2019-12-09 | 2024-08-27 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
| EP4146218A4 (en) * | 2020-05-04 | 2024-08-28 | Ascentage Pharma (Suzhou) Co., Ltd. | METHODS OF TREATING CORONAVIRUS INFECTIONS |
| EP4268834A4 (en) * | 2020-12-28 | 2024-10-16 | MD Healthcare Inc. | Composition for preventing or treating eye diseases comprising micrococcus luteus-derived extracellular vesicles |
| WO2022187141A1 (en) | 2021-03-01 | 2022-09-09 | Deciduous Therapeutics | Compounds for activating invariant natural killer t-cells and methods of use in eliminating inflammatory senescent cells |
| EP4322985A4 (en) * | 2021-04-13 | 2025-02-19 | Unity Biotechnology, Inc. | METHODS OF TREATMENT OF RETINAL VASCULOPATHIES |
| KR102625248B1 (ko) * | 2021-05-04 | 2024-01-16 | 주식회사 퓨전바이오텍 | 이미다졸린 유도체 화합물을 유효성분으로 포함하는 황반 변성 치료용 약학적 조성물 |
| WO2024051741A1 (zh) * | 2022-09-06 | 2024-03-14 | 西藏海思科制药有限公司 | 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用 |
| WO2025009608A1 (ja) * | 2023-07-06 | 2025-01-09 | 学校法人自治医科大学 | 生体内物質又は薬物の生体内半閉鎖系における濃度調節剤 |
| CN119925379B (zh) * | 2025-03-05 | 2025-09-05 | 中南大学湘雅医院 | Bcl3抑制剂在制备治疗青光眼的药物中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| ES2343706T3 (es) | 2001-04-11 | 2010-08-06 | Sumitomo Metal Industries, Ltd. | Junta roscada para tuberias de acero y proceso de tratamiento superficial de las mismas. |
| US9804295B2 (en) | 2005-05-05 | 2017-10-31 | Novartis Ag | Ophthalmic devices for sustained delivery of active compounds |
| WO2009094466A2 (en) | 2008-01-22 | 2009-07-30 | University Of Florida Research Foundation, Inc. | Contact lenses for extended release of bioactive agents containing diffusion attenuators |
| US8353856B2 (en) | 2008-11-05 | 2013-01-15 | Abbott Medical Optics Inc. | Glaucoma drainage shunts and methods of use |
| KR101762724B1 (ko) | 2011-01-25 | 2017-07-28 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법 |
| EP2922544B1 (en) | 2012-11-21 | 2018-08-01 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
| CN105246882A (zh) * | 2013-01-16 | 2016-01-13 | 密执安大学评议会 | BCL-2/Bcl-xL抑制剂和使用所述抑制剂的治疗方法 |
| JP2016516808A (ja) * | 2013-04-21 | 2016-06-09 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． | Ｂｃｌ−ｘＬおよび／またはＢｃｌ−ｗの活性および／または量を下方制御するための薬剤 |
| US20150038140A1 (en) | 2013-07-31 | 2015-02-05 | Qualcomm Incorporated | Predictive mobility in cellular networks |
| WO2015017536A1 (en) | 2013-07-31 | 2015-02-05 | The Board Of Trustees Of The Leland Stanford Junior University | Method and system for evaluating progression of age-related macular degeneration |
| CA2939121C (en) * | 2014-01-28 | 2020-11-24 | Mayo Foundation For Medical Education And Research | Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease |
| CA2981753A1 (en) * | 2015-02-06 | 2016-08-11 | Unity Biotechnology, Inc. | Compounds and uses in treatment of senescence-associated conditions |
| US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| US20180193458A1 (en) * | 2015-07-08 | 2018-07-12 | Unity Biotechnology, Inc. | Compositions and methods for treating senescence-associated diseases and disorders |
| US11111259B2 (en) * | 2015-12-18 | 2021-09-07 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
-
2018
- 2018-08-13 AU AU2018314280A patent/AU2018314280B2/en active Active
- 2018-08-13 CA CA3072673A patent/CA3072673A1/en active Pending
- 2018-08-13 CN CN201880063962.8A patent/CN111372598A/zh active Pending
- 2018-08-13 MX MX2020001644A patent/MX2020001644A/es unknown
- 2018-08-13 EP EP18188799.3A patent/EP3441069B1/en active Active
- 2018-08-13 JP JP2020507573A patent/JP7278257B2/ja active Active
- 2018-08-13 EP EP23166363.4A patent/EP4234025A3/en active Pending
- 2018-08-13 WO PCT/US2018/046553 patent/WO2019033119A1/en not_active Ceased
-
2020
- 2020-02-10 MX MX2025004366A patent/MX2025004366A/es unknown
-
2023
- 2023-05-08 JP JP2023076763A patent/JP2023100864A/ja active Pending
- 2023-10-16 AU AU2023251388A patent/AU2023251388B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530470A5 (enExample) | ||
| AU2023251388B2 (en) | Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells | |
| JP6629840B2 (ja) | 眼の疾患および障害を処置するための化合物 | |
| US20110117189A1 (en) | Ophthalmic compositions for treating pathologies of the posterior segment of the eye | |
| US11865123B2 (en) | Methods of inhibiting pathological angiogenesis | |
| CN109996814B (zh) | 多激酶抑制剂及在眼部纤维化中的用途 | |
| US10426783B2 (en) | Therapeutic agent for ocular fundus disease | |
| JP5934229B2 (ja) | 眼血管疾患の処置のための投与計画 | |
| US20100137342A1 (en) | Methods for treating vascular disruption disorders | |
| US20230025836A1 (en) | Eye drop composition for preventing or treating eye disease | |
| JP4150846B2 (ja) | ステロイドを有効成分とする網脈絡膜疾患治療剤 | |
| RU2024106207A (ru) | Лечение глазных болезней типа дегенерации желтого пятна, глаукомы и диабетической ретинопатии с помощью лекарственных средств, устраняющих стареющие клетки | |
| CN113768929B (zh) | Fdi化合物在眼科疾病中的用途 | |
| WO2002078713A1 (fr) | Medicaments contre les affections retiniennes et choroidiennes contenant des steroides comme principe actif | |
| EP2875811A1 (en) | Use of dobesilate for treating ocular haemorrhages |